Clene Inc. (Nasdaq: CLNN) announced on September 15, 2026, the pricing of a registered direct offering to existing shareholders. The company agreed to sell 1,219,513 shares of its common stock at a price of $3.28 per share. The transaction is expected to generate gross proceeds of approximately $4.0 million.
The offering is being led by Clene’s Chairman of the Board of Directors, David Matlin, alongside founding investor Kensington Capital Holdings, the company’s Chief Executive Officer, and other existing stockholders. The closing of the transaction is scheduled for September 17, 2026.
Clene intends to use the net proceeds from the sale, combined with its existing cash reserves, to fund general corporate expenses. Specifically, the company stated the funds will support the continued regulatory dialogue and the preparation of regulatory filings for its lead drug candidate, CNM-Au8. The proceeds will also cover expanded access protocols, potential future commercialization efforts, and manufacturing expansion.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-286058) previously filed with the Securities and Exchange Commission. A legal opinion from Dorsey & Whitney LLP regarding the validity of the shares was also filed as part of the current report.
